Competitive intelligence on small-molecule drugs and the 80,000 patents covering them

Simple flat-rate subscription plans

Ultimate Plan

$495/ month or  $2,495/ year

Tradename: VYTORIN

Summary for Tradename: VYTORIN

Suppliers: see list5
2013 Sales:$858,576,000
patent expirations by year for

Clinical Trials for: VYTORIN

Vytorin in the Treatment of Alopecia Areata
Status: Recruiting Condition: Alopecia Areata

Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
Status: Completed Condition: Hypercholesterolemia; Hyperlipidemia

Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 a Subfraction of LDL in Patients With Metabolic Syndrome.
Status: Not yet recruiting Condition: Metabolic Syndrome

Vytorin Reexamination Study (0653A-174)
Status: Completed Condition: Primary Hypercholesterolemia and Homozygous Familial Hypercholesterolemia (HoFH)

Clinical Trial of Zocor (Simvastatin) and Vytorin (Ezetimibe/Simvastatin) in Adolescents With Type 1 Diabetes
Status: Completed Condition: Type 1 Diabetes Mellitus; Dyslipidemia

IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe/Simvastatin) vs Simvastatin (P04103 AM5)
Status: Active, not recruiting Condition: Hypercholesterolemia; Myocardial Infarction

Vytorin As Strategy To Reduce Dislipidemia In Adults
Status: Completed Condition: Hyperlipidemia

Comparison of the Effect of Vytorin 10/80 Tablet Split Into 4 and Simvastatin 20 Milligrams on Low-density Lipoprotein (LDL) Cholesterol
Status: Completed Condition: Hypercholesterolemia

A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in Korea
Status: Completed Condition: Hypercholesterolemia

To Study the Effect of Vytorin on Intracellular Lipid and Inflammation in Obese Subjects
Status: Active, not recruiting Condition: Inflammation

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Msd Intl
ezetimibe; simvastatin
TABLET;ORAL021687Jul 23, 2004RXNo<disabled><disabled>
Msd Intl
ezetimibe; simvastatin
TABLET;ORAL021687Jul 23, 2004RXNo5,846,966*PED<disabled>Y<disabled>
Msd Intl
ezetimibe; simvastatin
TABLET;ORAL021687Jul 23, 2004RXNoRE37721*PED<disabled><disabled>
Msd Intl
ezetimibe; simvastatin
TABLET;ORAL021687Jul 23, 2004RXNoRE42461*PED<disabled><disabled>
This preview shows a limited data set
Complete access is available with a Subscription
first patents previous patents next patents last patents

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: VYTORIN

Drugname Dosage Strength RLD Submissiondate
ezetimibe and simvastatinTablets10 mg/10 mg, 10 mg/20 mg, 10 mg/40 mg and 10 mg/80 mgVytorin7/27/2009

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000  2001  2002  2003  2004  2005  2006  2007  2008  2009 
 2010  2011  2012  2013 

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Connect with Social Media:

Follow DrugPatentWatch on Twitter Connect with DrugPatentWatch on Linkedin Drug Patents on LinkedIn

Copyright © 2002-2014 thinkBiotech LLC. ISSN: 2162-2639

Other thinkBiotech sites: BiotechUBiotechBlogJournal of Commercial Biotechnology